Monograph Details
|
|
Ob/Gyn
> Menopause and HRT
|
|
OGEN |
| Manufacturer |
|
Pfizer Labs |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Estrogen. |
| Generic Name |
|
Estrone sodium sulfate (as estropipate) 0.625mg, 1.25mg, 2.5mg; scored tabs. |
| Indications |
|
Moderate to severe vasomotor symptoms of menopause. Atrophic vaginitis. Osteoporosis prevention. Hypoestrogenism. |
| Children |
|
Not applicable. |
| Adults |
|
Menopause: 0.625–5mg daily, given cyclically (3 weeks on, 1 week off). Osteoporosis prevention (begin therapy soon after menopause): 0.625mg daily, given cyclically (25 days of a 31-day cycle). Hypoestrogenism: 1.25–7.5mg daily for 3 weeks. Repeat course if withdrawal bleeding does not occur within 8–10 days after discontinuing. See literature. Reevaluate periodically. |
| Contraindications |
|
Breast or estrogen-dependent carcinoma. Undiagnosed abnormal genital bleeding. Thromboembolic disorders. Thrombophlebitis. Pregnancy (Cat.X). |
| Precautions |
|
Patients with an intact uterus should almost always receive a progestin to avoid endometrial hyperplasia. Cardiovascular disease. Hepatic dysfunction. Gallbladder disease. Conditions aggravated by fluid retention. Bone disease associated with hypercalcemia. Do initial complete physical and repeat annually (include BP, mammogram, and PAP smear). Discontinue if jaundice or hypertension occurs and at least 2 weeks before surgery associated with thromboembolism. Nursing mothers. |
| Adverse Reactions |
|
See literature. GI upset, breakthrough bleeding, edema, weight changes, mastodynia, hypertension, intolerance to contact lenses. |
| How Supplied |
|
Tabs—100 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
